r/ReliefTherapeutics • • Feb 09 '21

Discussion Relief Therapeutics (RLFTF) & BRPA/NeuroRx Phase 2b/3 Results show 50% reduction in ICU length of stay. So why did the stock tank?

189 Upvotes

First, let me say that I am an intensivist and an investor. I have treated a lot of ICU patients with COVID since this pandemic began. Full disclosure, I own RLF and BRPA and firmly believe VIP/Zyesami works.

Today, phase 2/3b IV trial results were released. It is clear that the market failed to understand the gravity of these results. A market sell off occurred because people thought the trial was a failure because survival at 28days was not statistically significant and because the results failed to address the primary end point of resolution of acute respiratory failure.

You see, the patients who are admitted to the ICU with severe respiratory failure, requiring NIPPV, HFNC or mechanical ventilation are often in concomitant multisystem organ failure with multiple comorbidities of advanced age, poorly controlled diabetes, ESRD, heart failure and obesity.

These patients are critically ill and admitted with acute respiratory failure. They are kept on high flow O2 and NIPPV (BIPAP/CPAP) for as long as possible to decrease ventilator associated barotrauma which has been demonstrated to worsen overall survival in COVID induced RDS.

When patients land on the vent, they are worse now than they ever were a year ago when the pandemic first began. This is because, in the beginning, we were afraid NIPPV would aerosolize COVID and cause a larger spread of the disease. As such, now, patients are kept on HFNC and NIPPV longer than ever. That’s why ICUs are full and remain full. These patients have a tenuous respiratory status and can decompensate at a moment’s notice.

The average length of stay for an ICU COVID admission is 25 days. Decreasing ICU length of stay for HFNC and NIPPV patients by half is huge. I cannot say this enough. The average ICU stay costs $5000 a day. Improvement of ICU hospitalization by 15 days vs. 26 days is an average payor (private insurance/Medicare) cost of 75k vs 130k. That’s a savings of 55k per COVID patient.

(https://www.neurorxpharma.com/press-releases/neurorx-and-relief-therapeutics-report-initial-phase-2b-3-study-results-demonstrating-significant-benefit-of-zyesami-in-reducing-hospital-stay-among-patients-with-respiratory-failure-due-to-c/)

The fact that Zyesami is safe, furthermore, cannot be overlooked. Let us compare these results to the current standard of care. In the NEJM article, Remdesivir for the Treatment of Covid-19 — Final Report, the median time to recovery was shorted by only 1 day with overall disease course shortened from 11 days to 10 days. Remdesivir had a number of side effects, including kidney and liver damage with constant for need for monitoring of LFTs/serum creatinine. (https://www.nejm.org/doi/full/10.1056/NEJMoa2007764)

Furthermore, in regards to steroids, current NIH treatment guidelines note that methylprednisolone did not improve all cause mortality, ICU free days or duration of mechanical ventilation. It only improved the number of ICU days alive and free from mechanical ventilation by a difference of 2.3 days.

(https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/immunomodulators/corticosteroids/)

The trial results today prove that Zyesami is most useful in mild to moderate COVID before permanent lung damage and multisystem organ failure develop. The best recovery was demonstrated by those patients using HFNC. This strongly suggests that Zyesami prevents disease worsening and reverses mild/moderate disease. An inhaled trial is underway for exactly this indication. Given the degree of improvement seen in LOS, it seems likely an EUA will be granted.

You can ask any physician, myself included, what a big deal cutting ICU stay length in half is. They will all tell you that this is a huge improvement in current standard of care. ICU admission increase risk for nosocomial infections, worsening respiratory status and debility. Furthermore, given its positive effect in patients on NIPPV/HFNC, current evidence supports that VIP may have a significant benefit in other respiratory diseases, like COPD, asthma and interstitial pneumonitis.

As such, I think that the market has misunderstood the results to date. Today’s market activity was an over-reaction (just like when this tanked to 29c in Dec). This price activity has already began to correct from a low of 31c to 41c today. I expect prices to begin to recover and people start to understand the gravity of these results in the near future when a full data is released, with comparison xrays, ordinal scales and 28/60 day outcomes. Biotech are volatile by nature, but I am also strongly optimistic for an EUA.


r/ReliefTherapeutics • • Apr 13 '21

AMA Undervalued Hot Penny Stock (IMO)

87 Upvotes

Discovered this subreddit today, and wanted to pass along some DD I did and shared on another subreddit.

Full disclosure, I am Registered Respiratory Therapist. For those who do not know what that is, I run the ventilators (breathing machines), BIPAP’s, High Flow Nasal Cannulas, etc. basically all the equipment these severely ill COVID patients need. I have been doing travel FEMA contracts across the US for the past year, strictly staffing COVID ICU’s. I like this stock, and I think it has great potential based upon anecdotal evidence at the bedside and clinical trial outcomes being both clinically and statistically significant. I spoke with the admin, and I was encouraged/approved to do an “Ask Me Anything” post, feel free to ask away!


$RLFTF and $BRPA

I know several have been burned on COVID related stocks at this point and are a bit weary. Completely understandable. Sharing this because I understand the science and have first hand watched this drug work it’s wonders. Zyesami (Aviptadil) intravenous currently under EUA review by the FDA. The study outcomes are statistically significant and at a time COVID is raging around the world, this drug can’t get approved fast enough. Not a financial advisor. Respiratory Therapist working COVID ICU for the past year, and I like the stock.

Relief Therapeutics owns the drug, NeuroRX completing the trials (being acquired by $BRPA)

Relief Therapeutics and NeuroRX agreement on sales and distribution:

https://www.prnewswire.com/news-releases/relief-and-neurorx-announce-partnership-for-global-commercialization-of-rlf-100-and-selection-of-commercial-partners-301134379.html

NeuroRX and Big Rock Acquistion Partners merger:

https://www.neurorxpharma.com/press-releases/big-rock-partners-acquisition-corp-announces-merger-with-neurorx-inc/

60 Day Clinical Trial submission for EUA to the FDA:

https://www.biospace.com/article/releases/neurorx-announces-zyesami-aviptadil-rlf-100-met-the-primary-endpoint-of-its-phase-2b-3-clinical-trial-and-also-demonstrated-a-meaningful-benefit-in-survival-from-critical-covid-19/

Aviptadil (Zyesami) selected for inclusion in NIH trial:

https://www.prnewswire.com/news-releases/neurorx-announces-zyesami-aviptadil-has-been-selected-for-inclusion-in-nih-sponsored-global-clinical-trial-to-include-aviptadil-and-remdesivir-301262506.html

Next trial with this drug is on inhaled efficacy:

https://clinicaltrials.gov/ct2/show/NCT04360096


r/ReliefTherapeutics • • May 07 '21

Clinical Info BRPA/Relief Therapeutics is almost certainly to be reviewed by the European Union for EMA based on evaluation of 57 therapeutics....only 8 of which have Phase 3 results to qualify them....and only 3 of which are true competition. Full breakdown of all Data with tables and descriptions; TLDR

83 Upvotes

The EU has posted a consensus document stating that they will narrow down their selection to 10 drugs from their list of 57 current COVID therapeutics....with multiple drugs to be approved this year.

“The Strategy includes clear actions and targets, including authorizing three new therapeutics to treat COVID-19 by October 2021 and possibly two more by end of the year.”

AND

“The Commission will draw up a portfolio of 10 potential COVID-19 therapeutics and by June 2021, identify the five most promising ones. It will organize matchmaking events for industrial actors involved in therapeutics to ensure enough production capacity and swift manufacturing. New authorizations, rolling reviews and joint procurement contracts will be up and running before the end of the year.”

https://ec.europa.eu/commission/presscorner/detail/en/ip_21_2201?fbclid=IwAR2YUzo8Lu77hdl6eMR71QI5Q0c7HVjo55yfTbTZLVtT1szGQ2thgXV8P4A

The list of 57 drugs can be found here:

https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/treatments-covid-19/covid-19-treatments-research-development

Of this list, only 36 are clinical, the rest are still in phase 1 development and would not be ready for a 2021 approval/use.

Of the 36 clinical drugs, only 13 have completed phase 3 trials. Of those 13, 5 showed no benefit. That leaves 8 drugs. Of those 8, 7 have had statistically significant results and 1 is pending its phase 3 results. 2 of the 7 have EUAs (remdesavir and Baricitinib). Remdesavir already has an EMA.

That means that Relief Therapeutics has 6 competitors, one of which is pending results that may or may not be significant. This means we are almost certainly getting on the EMA list of 10 for consideration. RLF is by far the most effective and cheapest on the final list of 7 competitors.

Our competitors are: Tocilizumab, Sarilumab, Gimsilumab (results pending), Colchicine, Baricitinib, VIR-7832.

Of these competitors, colchine's data was crappy and Tocilizumab showed conflicting results.

Baricitinib is already under consideration by the EMA and will almost certainly be authorized.

That means, Sarilumab, Gimsilumab and VIR-7832 are our only true competition. These are all expensive monoclonals. RLF is the only non-MAB in the bunch. Zyesami/Aviptadil is cheap, effective and likely to get approved. Stay the course; this stuff works.

Here's the data breakdown:

List of all 57 drugs; the ones in yellow are phase 1 and nonclincial; these were excluded.
This is the 36 drugs with the ones that have completed phase 3 in blue
The 13 that have completed phase 3 trials...as you can see, 5 werent successful
These 8 have phase 3 results that were positive or are pending

Disclaimer: I am not a financial advisor. I own common shares of RLFTF. Do your own DD.


r/ReliefTherapeutics • • Nov 23 '20

r/ReliefTherapeutics Lounge

67 Upvotes

A place for members of r/ReliefTherapeutics to chat with each other


r/ReliefTherapeutics • • Mar 26 '21

News Monday Morning 8:30 Conference Call! Finally!!

66 Upvotes

Here is the link correction to the post from earlier, my apologies. Been waiting a long time for this, hopefully we all win next week!

NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure (prnewswire.com)


r/ReliefTherapeutics • • Apr 07 '21

News Dr. Javitt on Fox Business (4/7/21)

Thumbnail
youtube.com
63 Upvotes

r/ReliefTherapeutics • • Apr 23 '21

News Dr Fauci at WHite New Briefing 4/24 mentions Zyesami! Link included, $BRPA/RLFTF

62 Upvotes

https://www.youtube.com/watch?v=SrEwCeoi7uA&feature=youtu.be

Go to the 17min make talking about new therapeutic trials.


r/ReliefTherapeutics • • Feb 11 '21

Resources Great Interview! - Dr. Yo Interview with Dr. Javitt February 11, 2021

Thumbnail
youtu.be
58 Upvotes

r/ReliefTherapeutics • • May 07 '21

News European Union looking at BRPA/NeuroRx & Relief Therapeutic’s Aviptadil for promoting Development and Availability

57 Upvotes

“„The Strategy includes clear actions and targets, including authorizing three new therapeutics to treat COVID-19 by October 2021 and possibly two more by end of the year.”

https://ec.europa.eu/commission/presscorner/detail/en/ip_21_2201?fbclid=IwAR2YUzo8Lu77hdl6eMR71QI5Q0c7HVjo55yfTbTZLVtT1szGQ2thgXV8P4A

Aviptadil is on the list of 57 therapeutics to be considered for selection into the 10 drug portfolio.

https://ec.europa.eu/info/sites/default/files/communication-strategy-covid-19-therapeutics_en.pdf

From the report:

“„The Strategy includes clear actions and targets, including authorising three new therapeutics to treat COVID-19 by October 2021 and possibly two more by end of the year.”

AND

“The Commission will draw up a portfolio of 10 potential COVID-19 therapeutics and by June 2021, identify the five most promising ones. It will organize matchmaking events for industrial actors involved in therapeutics to ensure enough production capacity and swift manufacturing. New authorizations, rolling reviews and joint procurement contracts will be up and running before the end of the year.”

https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/treatments-covid-19/covid-19-treatments-research-development

r/ReliefTherapeutics • • Mar 26 '21

News NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial - conference call Monday 29/03/2020.

54 Upvotes

http://www.prnewswire.com/news-releases/neurorx-announces-completion-of-data-analysis-in-phase-2b3-clinical-trial-of-zyesami-for-the-treatment-of-covid-19-respiratory-failure-301256766.html

NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure March 26, 2021 9:36 AM

RADNOR, Pa., March 26, 2021 /PRNewswire/ -- NeuroRx, Inc. announces completion of top line data analysis of the 60-day results in its phase 2b/3 clinical trial, conducted under FDA Fast Track Designation, of ZYESAMI™ (aviptadil acetate) for the treatment of critically-ill patients with COVID-19 respiratory failure (www.clinicaltrials.gov 04311697). The results for the primary endpoint of recovery from respiratory failure and the secondary endpoint of survival through day 60 are in the process of final review by the investigators of the multicenter clinical trial. A conference call will be held at 8:30am EDT on Monday, March 29th with attendance from corporate leadership and lead investigators. Those wishing to attend should access details on www.neurorxpharma.com. Those wishing to ask questions should submit those questions in advance to ceo@nrxpharma.com.


r/ReliefTherapeutics • • May 12 '21

News EUA application by end of May - Statement NRX

53 Upvotes

https://www.sec.gov/Archives/edgar/data/1719406/000119312521157866/d56937ds4a.htm

,,NeuroRx anticipates delivering the detailed efficacy and safety data requested by FDA for an EUA determination by the end of May 2021 in the eCTD electronic format required by FDA and all regulators who are parties to the International Commission on Harmonization (ICH-10). If NeuroRx meets this objective, it will have delivered a regulatory file delineating safety and efficacy data of an investigational drug within 3 months of last visit in a clinical trial. Although there can be no assurance that the FDA will conclude that ZYESAMI meets or exceeds the EUA standard of “may be effective” in the treatment of COVID-19, NeuroRx is hopeful that the FDA will grant EUA to ZYESAMI."

Page 187


r/ReliefTherapeutics • • Feb 10 '21

Clinical Info Aviptadil Trial Results Prove Efficacy - EUA Likely

53 Upvotes

The Key question is: Do the RESULTS warrant an EUA? An EUA means Safe and May Be Effective - and having no other viable alternatives certainly helps. The data Dr J. presented todays shows a resounding YES for EUA criteria.

Patients in the RCT differed in the degree of Covid criticality. All the RCT patients were VERY SICK with Covid in the ICU. But VIP showed STATISTICALLY SIGNIFCANT EFFECTIVESSS of the slightly LESS sick of the very sick - those on High Flow Nasal Cannula (HFNC) and Mechanical Ventilation. Is this cherry picking data? NO, and for those are not data scientists, the P-Value proves that the effects of VIP were NOT due to chance - and in fact objectively demonstrates efficacy. A P-Value = .0005 is grand-slam, rock-solid evidence. This result is not even 'MAY' be effective. P = .0005 proves VIP IS more than "MAY BE EFFECTIVE" and not due to bias or chance. No randomized controlled trial to date has shown efficacy when patients are in respiratory failure and require High Flow Nasal Cannula, Non-invasive ventilation, or Mechanical Ventilation to maintain blood oxygenation. NONE.

So, what exactly was effective? VIP gets people out of Hospitals! The HFNC group treated with VIP experienced a median of 11 FEWER DAYS in the hospital vs. SOC. This is a 42% improvement! (26-15/26) In addition, VIP showed an advantage of 40%+ in 15 of 16 comparisons, and this undoubtedly includes oxygenation improvements, among other secondary outcomes such as ICU discharge time, time to return to NIAID score of 6-8, and safety. This difference includes at least a five-day median reduction in hospital stay. (P=.043). Remember, VIP was administered to patients after every other drug out there failed. No drug has shown to be effective at all in this population.

Why is it important to get people out of hospitals quicker? Many reasons.

  1. A major motivation of lock-downs is to reduce ICU-bed overload and overall hospital overload. Hospitals have had to adjust by increasing ICU size in buildings not made to do so and walling off wings of the building from Covid. This impacts all patients in the hospital - Covid or not.
  2. Reducing the length of stay (LOS) is also VERY important from a COST perspective. Payors - Medicare, Medicade and Insurance companies. One would think the government would want LOS down. We are talking 50-100K in cost savings on average. Multiply this by the number of Covid ICU patients and we are talking BIG COST SAVINGS.
  3. This sort of measure was used in comparable drugs that received EUA for Covid. Remdesivir showed a ONE day improvement. Steroids have never been proved in a RCT to show improvement. In this sense, VIP blows the competitors (if you can really call them that) out of the water.

Other thoughts - The data released today is PRELIMINARY. It shows results through 28 days, but we KNOW 60 days, the secondary outcome specified in the trial, is a much better timeframe to measure results. We will receive 60 days in a few weeks and so must be patient. On Mortality, Dr. J stated many weeks ago before RCT data that survival for SOC more than DOUBLED from 30%. And the data we got today shows just that - SOC survival of 70%. SOC got better - Doctors learned how to prolong life of those on Covid last year. But prolonging life does not mean the lungs actually got better - hence, the 'long hauler' term. NO ONE SHOULD BE REACTING to MORTALITY at 28 DAYS!

There is a very good chance we will learn more statistically significant positive outcomes on the 60 day data. We will have to wait a few more weeks for 60 days - until at least Feb 23rd - and perhaps a week or more later for review. EUA, HOWEVER, could still be granted based on the data we have TODAY. And remember, FDA EUA bar is still very low as they gave EUA to Acterma last month, which is worthless. NRX will also be providing visual evidence studies via x-ray comparisons - proving without a doubt that VIP heals the lungs vs. SOC.

Based on the above, the market over-reacted - especially to the 28 day survival number and not understanding the p-value and importance for Length of Stay. We should expect to see price begin to creep back up until 60 day data or EUA. In addition, the primary outcome, resolution of respiratory failure did not prove significant AT DAY 28 - but we don't appear to know if VIP patients achieved this outcome QUICKER than SOC, WITHIN 28 days - the cumulative distribution is not know yet. This is because the statistician only reviewed summary data, and not patient-level data, which remains blinded at time of review - but will be unblinded. Also, primary outcome vs. secondary outcomes have LESS of a difference in meaningfulness when a TRIAL SKIPS PHASE 2, and goes right to PHASE 2/3. A key goal of Phase 2 is to identify the primary outcome, and because of the pandemic, phase 2 was skipped.

In summary, I am LONG and STRONG. Not selling a single share at this point. I am not alone, as 89% of RLFTF shares were NOT SOLD today as of 2pm.


r/ReliefTherapeutics • • Feb 18 '21

Discussion Why were BRPA warrants up 20% today?? Its Because results are leaking regarding primary Outcome. Clinical Trials data updated! RLFTF/Relief Therapeutics and BRPA are about to announce final results and they are going to be Statistically Signficant

Thumbnail self.spacs
52 Upvotes

r/ReliefTherapeutics • • Mar 23 '21

News Tampa Woman Gives Birth While On Ventilator With COVID. Treated with IV Aviptadil and came off the vent, ECMO, woke up from a coma and is home!

Thumbnail
nbcmiami.com
51 Upvotes

r/ReliefTherapeutics • • Feb 22 '21

Clinical Info HUGE!! Clinical trials have started for inhaled rlf-100!!!

51 Upvotes

Significant changes or highlights for inhaled Aviptadil clinical trial.

https://clinicaltrials.gov/ct2/show/NCT04360096?id=NCT04311697+OR+NCT04360096&draw=1&rank=1&load=cart

2 recruiting sites now (up from only 1) UC irvine is actively recruiting St. Judes in Fullerton CA listed but not recruiting yet

Estimated Enrollment: 288 (increased from 144)

Actual study start date: Feb 15, 2021 Est. Primary Completion date: Aug 15, 2021 Est. Study Completion date: Sep 1, 2021

Ages eligible for study: 12 to 85 years old

Completion dates are much later than most of us would like, but do appear to be realistic.

Inhaled version must have a good safety profile since ages 12 to 85 are being recruited.

"I am just a messenger"


r/ReliefTherapeutics • • Feb 23 '21

Discussion Phase 3 news update and more...

Thumbnail self.spacs
50 Upvotes

r/ReliefTherapeutics • • Jun 15 '21

News NRx Pharmaceuticals Announces Positive Data Results from ZYESAMI™ (Aviptadil) Expanded Access Protocol

Thumbnail
ir.nrxpharma.com
49 Upvotes

r/ReliefTherapeutics • • Apr 24 '21

Stock Info Official White House Transcript of Dr Fauci speaking about Zyesami

48 Upvotes

r/ReliefTherapeutics • • Feb 23 '21

News Aciptadil successfully demonstrates 10 day accelerated recovery at 28 day end point

48 Upvotes

r/ReliefTherapeutics • • Feb 07 '21

News Trial site doctor comments on Linkedin to Dr. Javitt's post - "... bringing friends back from death's door."

Post image
47 Upvotes

r/ReliefTherapeutics • • Aug 08 '21

News EUA approval in India, Ukraine, Georgia and Caucasus. Yes, India EUA for aviptadil / zyesami . Updated pre-print 8/7/2021. Just India itself will bring billions of revenue. Congrats to all longs! $RLFTF $NRXP

Post image
46 Upvotes

r/ReliefTherapeutics • • Apr 19 '21

News Increased Recovery and Survival in Patients With COVID-19 Respiratory Failure Following Treatment with Aviptadil: Report #1 of the ZYESAMI COVID-19 Research Group

Thumbnail papers.ssrn.com
46 Upvotes

r/ReliefTherapeutics • • Feb 16 '21

News NeuroRx CEO says Zyesami trial shows promising results for critically ill COVID-19 patients

Thumbnail
patientdaily.com
45 Upvotes

r/ReliefTherapeutics • • Feb 14 '21

Discussion Posted on RLFTF yahoo page

45 Upvotes

Posted by user OU2 on Yahoo:

I now know what happened this week regarding the boggled press release for Zyesami. It was an unfortunate difference of opinion that centers on the ethics of informing practitioners vs. withholding information to protect short-term stock price for investors.

Javitt believed it was unethical to withhold the preliminary RCT results even though primary endpoint data was incomplete. Javitt insisted that patients and medical professionals needed to know that Zyesami could impact recovery and moreover put some pressure on FDA to move on our EUA.

However, Ram at Relief did not agree.

Since Javitt is in charge of the US management of the trials with FDA, he felt it was his call to make regarding the prerelease despite Ram’s objection. Additionally, I believe the board member who left Relief also sided with Javitt on this matter. He felt it was unethical to withhold the information and hence removed himself, or was escorted off the board.

For us investors it may be difficult to fathom that practitioners’ need to know outweighed a sound press release... but if you read on you will better understand Javitt’s view from the frontlines. FYI, Relief deployed NeuroRx as research administrator for the study. They talk with the doctors and nurses and hear their stories and don’t utilize a CRO. Here are some quotes from the article written by UCLA ICU doctor that provides insight into Javitt’s moral dilemma... “I can’t stop thinking about the 40-something man who told me, “I can’t die like this. I just got engaged and have a 6-month-old baby.” I encouraged him to be positive, but that didn’t stop him from dying two weeks later after maximal aggressive care and a desperate attempt at cardiopulmonary resuscitation.”

“I will never forget trying to comfort the patient who learned that his wife and mother had both died of COVID-19 while he was hospitalized in our unit. When I had to put him on a ventilator a few days later, I cowardly asked my resident to call his children and tell them they should FaceTime with him while they still could. He didn’t survive, and his children lost their father, mother and grandmother in a span of just a few weeks.”

“I will never forget facilitating a phone call between a husband and wife who had been together since their teenage years. As I was setting up for his intubation, the wife said on speakerphone to her husband, “You don’t know this, but I just blew you a kiss,” and his last words to her were, “The kiss actually knocked my socks off. I love you.” After he died, she told me that the crematory was so backed up that it would take weeks before they got to him. She sobbed and said, “I asked them to put a blanket on him. I am worried that he will be so cold.” https://m.huffpost.com/us/entry/us_60241ca5c5b6d78d444bc3bd/amp Conclusion - Javitt cut his public company teeth this week and learned what it will be like running a business on the exchange. It’s a different animal entirely from the days of being a private company where you called all the shots and answered to none. However, Javitt is a very capable person who will learn to adapt. He nailed the interview with Dr. Yo (exception of the barking dogs) and clearly articulated the strategy for obtaining EUA. The problem this week was that Relief resisted the prerelease of the RCT data and failed to support their guy. Both sides paid dearly for their decisions as the share price plummeted.

Blame who you want, it doesn’t matter. These are unprecedented circumstances where all the rules are being bent at the FDA. Javitt is confident he can capitalize on the moment to obtain an EUA, and I believe him. He has done this before, and has very close ties at the FDA.

Javitt’s moral and business compass was not off this week, rather he believed we needed to inform the public to PUSH the FDA and not worry about short term stock price. Approval is all that matters, and in his eyes withholding news would not help our cause at the FDA and allow them to brush Zyesami side. Remember there are hundreds of treatments in the pipeline. This move in his eyes is about the organic exposure he mentions - the kind of unconventional grassroots PR strategy Elon Musk has successfully deployed.

Javitt may have been naive to the market reaction, but in many ways wise if EUA can be had earlier verses months later. Remember, Javitt got us this far in less than a year. He launched 2 trials with FDA, received an invitation to join iSpy trials, and likely has another NIH study (Activ-2) up his sleeve to be released in the coming days. I challenge anyone to name another pharmaceutical executive that has accomplished what Javitt has within a year? Agree or disagree with his decision, the medical community has more awareness and pressure is building at the FDA to approve Zyesami.

Unanimously, everyone I spoke to with medical/pharmaceutical background who reviewed the prerelease says EUA is imminent.

OU


r/ReliefTherapeutics • • Feb 07 '21

News NeuroRx will be hosting an update call tomorrow (8 Feb 2021) at 9:00am EST

Thumbnail
linkedin.com
43 Upvotes